ovarian ablation

ovarian ablation

Ovarian suppression Gynecology Surgery, RT, or chemotherapy to block ovarian hormonal activity
Mentioned in ?
References in periodicals archive ?
Medical ovarian ablation was performed in 47.4% of patients aged 35 years and younger and 68.7% in patients aged >35 years (p=0.004).
In this study, despite less frequent amenorrhea due to chemotherapy in the [less than or equal to]35 age group, patients with amenorrhea with medical ovarian ablation and/or chemotherapy showed no survival advantage compared with those who did not develop amenorrhea.
Ovarian ablation has been associated with improved overall survival and disease-free survival among these patients.
Two major clinical trials, the SOFT and TEXT trials, explored the benefit of ovarian ablation in the adjuvant treatment of early stage premenopausal breast cancer.
DeBoer et al., "An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer," Breast Cancer Research and Treatment, vol.
The addition of a GnRH (gonadotropin-releasing hormone) agonist (or ovarian ablation) to tamoxifen is indicated in patients at higher risk who remain premenopausal after chemotherapy.
* induction of premature menopause by therapy (i.e., chemotherapy and surgical or medical ovarian ablation)
The recent improvement in breast cancer survival can be credited to systematic screening programs, greater public awareness, earlier surgery, improved methods of achieving local control, more effective chemotherapy, tamoxifen, ovarian ablation, and advances in radiation therapy, he said at a breast cancer symposium sponsored by the San Antonio Cancer Institute.
For example, for women age 50 and younger, ovarian ablation -- the destruction or removal of the ovaries by radiation or surgery -- proved just as effective as chemotherapy.
11 LANCET urges cancer specialists to reexamined ovarian ablation in light of new findings.
SAN FRANCISCO -- Ovarian ablation or suppression shows promise as an adjuvant therapy in breast cancer, particularly in premenopausal women with receptor- positive lesions.
Two proposed etiologies are direct pharmacologic neurotoxicity or loss of estrogen's neurocognitive protective effect secondary to chemotherapy-induced ovarian ablation.